Provided by Tiger Fintech (Singapore) Pte. Ltd.

ENDRA Life Sciences Inc

3.45
-0.2100-5.74%
Post-market: 3.490.0400+1.16%19:46 EDT
Volume:55.64K
Turnover:194.78K
Market Cap:2.55M
PE:-0.06
High:3.58
Open:3.50
Low:3.38
Close:3.66
Loading ...

ENDRA Life Sciences Inc. Faces Nasdaq Non-Compliance Over Stockholders' Equity, Given 45 Days to Submit Remedial Plan

Reuters
·
30 May

ENDRA Life Sciences Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
30 May

ENDRA Life Sciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
16 May

BRIEF-ENDRA Life Sciences Provides A Business Update And Reports First Quarter 2025 Financial Results

Reuters
·
16 May

ENDRA Life Sciences Q1 EPS $(1.86) Beats $(4.08) Estimate

Benzinga
·
16 May

ENDRA Life Sciences Reports Q1 2025 Net Loss of $1.0M, Down from $2.8M in Q1 2024, as Cost-Cutting Measures Improve Financial Efficiency

Reuters
·
16 May

Press Release: ENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results

Dow Jones
·
16 May

ENDRA Life Sciences Inc expected to post a loss of $4.08 a share - Earnings Preview

Reuters
·
09 May

Why Vertiv Holdings Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket

Benzinga
·
23 Apr

ENDRA Life Sciences Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
21 Apr

U.S. RESEARCH ROUNDUP-Lowe's, Netflix, Vulcan Materials

Reuters
·
21 Apr

ENDRA Life Sciences Inc : Ascendiant Capital Markets Cuts Target Price to $50 From $75

THOMSON REUTERS
·
21 Apr

Top broker says Mesoblast shares can rocket 100%

MotleyFool
·
08 Apr

ENDRA Life Sciences FY 2024 GAAP EPS $(56.94) Misses $(47.46) Estimate

Benzinga
·
31 Mar

ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging Glp-1 Therapies

THOMSON REUTERS
·
31 Mar

ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies

Business Wire
·
31 Mar

ENDRA Life Sciences Inc - Q4 Net Loss 2024 $4.2 Mln

THOMSON REUTERS
·
31 Mar

ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update

THOMSON REUTERS
·
31 Mar

Press Release: ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update

Dow Jones
·
31 Mar

Mesoblast announces it entered into NDRA with CMS DHHS for Ryoncil

TIPRANKS
·
31 Mar